Results for "Medpace"

Recent regulatory filings reveal a series of insider stock transactions, with several chief executives and directors liquidating portions of their holdings. Simultaneously, companies like Santander and EKF Diagnostics have announced share repurchase programs to return capital to investors.

An analysis highlights Medpace Holdings (MEDP) as a promising investment bet, citing factors that contribute to its potential.

Bares Capital has reduced its investment positions in several companies, including Medpace Holdings Inc. and Wayfair Inc. This move indicates a trimming of their stakes in these firms.

Medpace (MEDP) has published the transcript of its second-quarter 2025 earnings call, providing details on its financial performance.

Medpace anticipates 2026 revenue to be between $2.805 billion and $2.885 billion, citing a constructive July environment and a reduction in cancellations as key factors for its optimistic outlook.

Madison Small Cap Fund has made strategic investments in Matador Resources Company due to its compelling valuation, increased its holdings in Medpace Holdings despite AI fears, and picked SiteOne Landscape Supply amid various growth drivers.

Medpace, a clinical research organization, anticipates converting $1.94 billion from its backlog over the next year, even as the company observes an increase in cancellations.

Medpace Holdings (MEDP) has reportedly seen benefits from the strong performance and demand within the GLP-1 drug market.

Financial analysts are evaluating whether Medpace Holdings, Inc. (MEDP) and Intuitive Surgical, Inc. (ISRG) are good investment opportunities. These articles provide insights into the current stock performance and future prospects of the companies.

Medpace shares declined even after the company reported better-than-expected Q1 earnings, with its 2026 guidance ranges including consensus estimates.

Barclays has upgraded Medpace and IQVIA, stating that concerns regarding the impact of AI on these companies are exaggerated.